Skip to main content

Table 3 Multiple generalised linear regression analysis of the determinants of total mean monthly costs (US$)

From: Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings

Variables

Value

% change from referent

p-value

Time period relative to ART initiation (months)

-4 to 4

384 (321 to 459)

80%

<0.001

 

4 to 12

238 (204 to 277)

12%

0.158

 

12 to 24

Referent

 

24 to 48

222 (182 to 270)

4%

0.705

Baseline CD4 count (cells/µL)

0 to 49

193 (164 to 227)

-10%

0.228

 

50 to 199

Referent

Current CD4 count (cells/µL)

0 to 49

352 (290 to 426)

65%

<0.001

 

50 to 199

Referent

 

200 to 349

190 (161 to 223)

-11%

0.16

 

350 to 499

166 (141 to 195)

-22%

0.002

 

≥500

158 (123 to 202)

-26%

0.017

Baseline viral load (copies/ml)

<100 000

Referent

 

≥100 000

220 (195 to 248)

3%

0.601

Current viral load (copies/ml)

<400

Referent

 

400 to 9 999

219 (191 to 250)

3%

0.717

 

10 000 to 99 999

195 (164 to 232)

-8%

0.317

 

≥100 000

249 (209 to 296)

17%

0.082

Overall adherence

<42%

264 (235 to 297)

24%

<0.001

 

42 to 74%

263 (233 to 295)

23%

0.001

 

75 to 92%

244 (218 to 273)

14%

0.019

 

≥92%

Referent

ARV regimen

First line

Referent

 

Second line

409 (255 to 656)

92%

0.007

NNRTI in first line

Nevirapine

197 (182 to 213)

-8%

0.042

 

Efavirenz

Referent

Duration of CD4 count monitoring (months)

≤6

181 (161 to 204)

-15%

0.008

 

>6

Referent

Sex

Male

206 (188 to 226)

-3%

0.463

 

Female

Referent

Age at starting ART (years)

<25

194 (164 to 230)

-9%

0.282

 

25 to 50

Referent

 

>50

230 (194 to 271)

8%

0.384

Referent cost

 

213 (178 to 256)

NA

NA